October 9, 2026
CSL Plasma’s full U.S. rollout intention matters, but the deal has conditions the market may be pricing too cleanly.
By the time most investors saw the headline on Thursday, the easy money in Haemonetics was already made. Shares climbed 17.46% to $119.47 on October 8, 2026 after CSL Plasma confirmed it intends to deploy NexSys PCS devices across its entire U.S. collection network. The question for buyers today isn’t whether the news was good. It obviously was. The question is whether the stock at $119 reflects what CSL actually committed to, or what investors are hoping it meant.
3X Over Lunch? (True Story)
I bought a tech stock back in 1998 for $5.
It nearly 10X’d to $45 in two years.
Then… one day I stepped out for lunch.
When I came back, the stock was at $135…
All said… a 2,600% gain.
I made a quarter of a million dollars in that single afternoon.
Right now, the same setup is forming again.
The Business
Haemonetics makes the equipment and single-use disposables that plasma collection centers use to draw plasma from donors. The recurring revenue from those disposables is the engine: once a center installs the hardware, consumable purchases follow for years. CSL expects the rollout to be completed by the end of calendar 2027, which could support higher device and disposable sales for Haemonetics as the installed base expands. That revenue stream is predictable, high-margin, and difficult for competitors to displace once an installed base is established.
Why Wall Street Is Paying Attention
CSL isn’t just any customer returning. It’s the customer whose exit explains a meaningful part of Haemonetics’ recent growth problem. In fiscal 2026, revenue fell 2.0% to about $1.33 billion, and the company has repeatedly highlighted that results look materially different when you exclude the prior-year CSL-related U.S. disposable revenue that lapped during fiscal 2026.
What changed between August and Thursday is scope. Haemonetics first disclosed the supply agreement in August, when it expected CSL to begin transitioning some of its U.S. plasma collection centers, with scope and timing not yet settled. On October 8, CSL said it expects to finish the rollout by the end of calendar 2027 and told Haemonetics it currently expects the switch to cover all of its current U.S. centers. That upgrade from partial to total coverage is what moved the stock. BTIG raised its price target from $110 to $130, maintaining a Buy rating. Citi went further, upgrading Haemonetics from Neutral to Buy and raising its price target to $123.
Why Did OpenAI CEO Sam Altman Put His Entire “Liquid Net Worth” Into Two Tiny Companies?
“I basically just took all my liquid net worth and put it into these two companies.”
Now a veteran Wall Street analyst believes the same breakthrough could create an extraordinary opportunity for ordinary investors.
What’s Driving the Opportunity
Needham’s analysis from August offers the best anchor for what full CSL deployment could mean. A complete CSL transition could eventually support approximately $183 million to $223 million in annual revenue after several years, assuming 6% to 8% compound annual growth and a 10% to 20% pricing premium for NexSys features. That is substantial relative to Haemonetics’ roughly $1.33 billion in fiscal 2026 sales, but it remains an analyst model rather than an established revenue run rate.
In its fiscal first quarter, Haemonetics posted adjusted earnings of $1.14 per share on revenue of $339.4 million. The company also raised its fiscal 2027 outlook, calling for revenue and adjusted earnings-per-share growth of 5% to 8%, up from a previous range of 4% to 7%. The CSL deal, at full scale, sits on top of that already-upgraded baseline.
What Could Go Wrong
Three things deserve more attention than Thursday’s trading implied.
First, the contract structure. The supply agreement is non-exclusive and does not contain minimum purchase commitments. CSL said it “currently anticipates” deploying across all centers. That language is intentional. Both companies emphasized that scope, timing and implementation details may change.
Nuclear Energy’s Comeback Could Spark Before 2026
Global energy demand is surging and one overlooked power source is quietly returning to the spotlight. New policy support and supply constraints are setting the stage for a surprising shift in the energy markets.
Second, the revenue timing. CSL expects the transition to finish by the end of calendar 2027, which falls within Haemonetics’ fiscal 2028. A back-loaded installation schedule would push most of the disposable revenue well beyond the current fiscal year. Haemonetics said it is not updating its previously issued fiscal 2027 guidance, and expects to provide an update during its second fiscal quarter earnings call in November 2026.
Third, the valuation. On widely followed market data services as of October 8, 2026, Haemonetics traded at roughly 58 times trailing earnings, reflecting heightened expectations and a premium valuation. Citi has also framed the upside in terms of share recapture, estimating that each 10% recapture adds $0.13 to EPS, which means the full upside materializes only if installation proceeds on schedule and at every center.
The Bottom Line
Haemonetics earned Thursday’s move. The upgrade from a partial CSL commitment to a full-network intention is a material change in the growth case, and the underlying business, with roughly a 59% gross margin and about $210 million in free cash flow in fiscal 2026, can support a premium. But buying at $119 means paying for an outcome that won’t be fully visible until the November earnings call at the earliest, under a contract with no volume guarantees. Investors who missed the gap-open have time. The next checkpoint is the November 2026 earnings call, where Haemonetics is expected to outline revenue timing, device placements and any change to its full-year outlook. That call is where the thesis either gets harder numbers or starts to fade. Patient buyers may find a better entry between now and then.
